MedNews

  • Drug Industry News
  • FDA News & Alerts
  • Health & Medical News
You are here: Home / Archives for MedNews

Healthy Lifestyle More Important than Supplements for Boosting Immune System

October 23, 2007 By MedNews 1 Comment

A healthy lifestyle—not vitamin and herbal supplemnts—is the most important factor in boosting your immune system, according to a recent report by Harvard Medical School.

While manufacturers of supplements make the claim that suplements "support immunity," there is currently little scientific evidence to support that claim, since scientists have not yet determined what level of immune system cells best helps the body resists disease.

According to the report, The Truth About Your Immune System: What You Need to Know, lifestyle factors that promote overall health are:

  • avoiding smoking
  • eating plenty of fruits, vegetables, and whole grains, and a diet low in saturated fat
  • exercising on a regular basis
  • maintaining a healthy body weight
  • controlling your blood pressure
  • drinking alcohol in moderation, if at all
  • getting enough sleep
  • Avoid infection, for example by frequent hand-washing and safe food preparation habits.

The 43-page report was edited by Dr. Michael N. Starnbach, Ph.D., professor of microbiology and molecular genetics at Harvard Medical School.

Source: Harvard Health Publications

Filed Under: General Health Tagged With: diet, exercise

FDA: Spontaneous Hearing Loss due to Viagra, Levitra and Cialis

October 20, 2007 By MedNews Leave a Comment

The United States Food and Drug Administration (FDA) approved labeling changes for Viagra, Cialis and Levitra that "more prominently display the potential risk of sudden hearing loss."

While rare, there have been reported incidents of single-sided hearing loss in patients taking the above erectile dysfunction drugs (Type 5 PDE5 inhibitors).

The labeling change was prompted by a published case of sudden hearing loss in a patient taking Viagra, and further studies found a total of 29 patients with sudden hearing loss.

There are no predictable warning signs for sudden hearing loss.

If you are taking these drugs and experience any hearing difficulty stop taking them at once and seek prompt medical attention.

From the FDA: "PDEF inhibitors are safe and effective for the treatment of ED when taken according to the labeling. However all drugs carry risks, and you should discuss any concerns you have regarding taking these products with your healthcare provider."

 

 

Filed Under: FDA News & Alerts, General Health, Sexual Health Tagged With: Cialis, ED, erectile dysfunction, Levitra, Viagra

Study Shows Brain Mechanism May Help Some Deal With Stress Better Than Others

October 19, 2007 By MedNews Leave a Comment

Some cope with stress much better than others, and a new study of mice shows that a naturally occurring mechanism in the brain promotes resilience to psychological stress.

Why is this important? In humans, stress is often associated with the development of some mental health issues such as post-traumatic stress disorder (PTSD) and depression. Results of the study, published online in the journal Cell, show that resistance to stress is not just a passive absence of stress vulnerability mechanisms as had been previously thought, but a biologically active process that results in specific adaptations in the brain’s response to stress.

The results are encouraging because a greater understanding of the brain’s function in regards to stress may help scientists discover how to enhance a naturally occurring mechanism in the brain that promotes resilience to psychological stress.

"We now know that the mammalian brain can launch molecular machinery that promotes resilience to stress, and we know what several major components are. This is an excellent indicator that there are similar mechanisms in the human brain," says Thomas R. Insel, MD, Director of the National Institute of Mental Health (NIMH).

In the study, smaller mice were put in cages with larger and more aggressive mice. Their vulnerability to stress was measured through such behaviors as social withdrawal after these encounters. While most mice adapted and continued social interactions after the stress event, some mice were overwhelmed by the interaction to the point that even after 30 days they were still avoiding social interaction with other mice.

The mice that were more traumatized by the stress showed more impulse firing by the cells that make dopamine, while the mice that were able to adapt maintained normal rates of impulse-firing due to a a protective mechanism—increased activity of channels that allow potassium to flow to the cells, which dampens the firing rate.

The higher firing rates in the traumatized mice led to more activity of a protein called BDNF, which had been linked to vulnerability in previous studies by the same researchers. With their comparatively lower rates of impulse-firing, the resistant mice did not have this increase in BDNF activity, another factor that contributed to resistance.

The scientists found that these mechanisms occurred in the reward area of the brain, which promotes repetition of acts that ensure survival. The areas involved were the VTA (ventral tegmental area) and the NAc (nucleus accumbens). In genetic experiments on the stress-resistant mice, many more genes in the VTA than in the NAc went into action in stressful situations, compared with vulnerable mice. Gene activity governs numerous biochemical events in the brain, and the results of this experiment suggest that genes in the VTA of resilient mice are working hard to offset mechanisms that promote vulnerability.

Another component of the study revealed that mice with a naturally occurring variation in part of the gene that produces the BDNF protein are resistant to stress. The variation results in lower production of BDNF, consistent with the finding that low BDNF activity promotes resilience.

The scientists also examined brain tissue of deceased people with a history of depression, and compared it with brain tissue of mice that showed vulnerability to stress. In both cases, the researchers found higher-than-average BDNF protein in the brain’s reward areas, offering a potential biological explanation of the link between stress and depression.

"The fact that we could increase these animals’ ability to adapt to stress by blocking BDNF and its signals means that it may be possible to develop compounds that improve resilience. This is a great opportunity to explore potential ways of increasing stress-resistance in people faced with situations that might otherwise result in post-traumatic stress disorder, for example," said Eric J. Nestler, MD, PhD, one of the study’s authors.

"But it doesn’t happen in a vacuum. Blocking BDNF at certain stages in the process could perturb other systems in negative ways. The key is to identify safe ways of enhancing this protective resilience machinery," Nestler added.

The study was published by Vaishnav Krishnan, Ming-Hu Han, PhD, Eric J. Nestler, MD, PhD, and colleagues from the University of Texas Southwestern Medical Center, Harvard University, and Cornell University, and was funded by the National Institute of Mental Health (NIMH).

Sources:

  • National Institutes of Health
  • Cell, October 18, 2007

Filed Under: Mental Health Tagged With: stress

New Drug Isentress (Raltegravir) Approved by FDA for HIV Treatment

October 18, 2007 By MedNews Leave a Comment

The U.S. Food and Drug Administration (FDA) has approved raltegravir tablets for treatment of Human Immunodeficiency Virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.

Raltegravir is the first agent of the pharmacological class known as HIV integrase strand transfer inhibitors, designed to interfere with the enzyme that HIV-1 needs to multiply. Raltegravir, sold under the trade name Isentress, received a priority review by the FDA.

"This is an important new product for many HIV-infected patients whose infections are not being controlled by currently available medications," said Janet Woodcock, M.D., FDA’s deputy commissioner for scientific and medical programs, chief medical officer and acting director, Center for Drug Evaluation and Research.

When used with other anti-HIV medicines, raltegravir may reduce the amount of HIV in the blood and may increase white blood cells, called CD4+ (T) cells, that help fight off other infections.

FDA’s approval of raltegravir is based on data from two double-blind, placebo-controlled studies in 699 HIV-1 infected adult patients with histories of extensive antiretroviral use. A greater proportion of the patients who received raltegravir in combination with other anti-HIV drugs experienced reductions in the amount of HIV in the blood, compared with patients who received placebo in combination with other anti-HIV drugs.

The most common adverse events reported with raltegravir were diarrhea, nausea, and headache. Blood tests also showed abnormal elevated levels of a muscle enzyme in some patients receiving raltegravir. Caution is advised when using raltegravir in patients at increased risk for certain types of muscle problems, including those who use other medications that can cause muscle problems.

Patients taking raltegravir may still develop infections, including opportunistic infections or other conditions that may develop in patients living with HIV-1 infection. The long-term effects of raltegravir are not known, and its safety and effectiveness in children less than 16 years of age has not been studied.

Raltegravir also has not been studied in pregnant women. Women who are taking HIV medications when they get pregnant are advised to talk with their physician or other health care professional about use of this drug during pregnancy, and about registering with the Antiviral Pregnancy Registry if they use raltegravir.

Raltegravir is distributed by New Jersey-based Merck & Co., Inc.

Source: U.S. Food and Drug Administration (FDA)

Filed Under: AIDS/HIV, Drug Approvals, FDA News & Alerts Tagged With: HIV/AIDS, Isentress, raltegravir

Cheap Running Shoes a Better Buy than Expensive Ones

October 18, 2007 By MedNews Leave a Comment

Why waste money on expensive running shoes when cheaper ones are as good, if not better? That’s the finding of a British research study which compared nine sets of running shoes in three price ranges, bought from three different manufacturers.


Forty three volunteers were used for the study. They were not told the prices, and were asked to rate the shoes for comfort.


Plantar pressure—the force produced by the impact of the sole when hitting the ground—was measured in eight different areas of the sole. It was found to be slightly lower in the cheaper shoes, although the difference between them and the more expensive shoes was not statistically significant. Comfort ratings varied, but again there no obvious difference between the shoes tested.


The authors of the research explained that running produces sizeable shock waves to the bones of the foot, which radiate to other bones in the body. The result is that runners often suffer from knee pain, stress fractures, muscle tears and osteoarthritis.


Running shoe manufacturers claim that the cushioning in more expensive running shoes gives better protection to the sole, and helps prevent these conditions.


Source: British Journal of Sports Medicine 2007; doi: 10.1136/bjsm.2007.038844

Filed Under: General Health Tagged With: exercise

Eye Scan May Help Early Diagnosis of Multiple Sclerosis (MS)

October 16, 2007 By MedNews Leave a Comment

Researchers have found that a five-minute eye exam called optical coherence tomography (OCT) that measures optic nerve damage may aide in spotting multple sclerosis (MS) early, as well as help track the progression of the disease.

While the definitive cause of MS is not known, most scientists believe that MS is an auto-immune disease, where the body’s immune system attacks the nervous system.

Currently, MS is diagnosed by patient history, clinical exams, and laboratory tests. The National MS Society says the preferred test, which detects plaques or scarring that may be caused by MS, is magnetic resonance imaging or an MRI.

In the OCT study, 40 multiple sclerosis (MS) patients underwent OCT scans. The results suggested an association between the retinal measurement and brain atrophy.

According to Johns Hopkins neurologist Peter Calabresi, M.D., an MRI "measures the result of many types of tissue loss rather than specifically nerve damage itself. With OCT we can see exactly how healthy these nerves are, potentially in advance of other symptoms."

OCT scans are also much faster and less expensive than MRI scans.

Dr. Calabresi adds that many of the MS symptoms, such as numbness, tingling, visual impairment, fatigue, weakness and bladder function disturbance, are the result of nerve cell degeneration, so a test that specifically measures nerve cell health is potentially the clearest picture of the status of the disease, though optic nerve damage can point to a number of diseases and is not a unique diagnostic tool for MS.

The National MS Society estimates that about 400,000 people have Multiple Sclerosis.

The study was published in the October, 2007 issue of Neurology.

Source: Johns Hopkins University

Filed Under: General Health Tagged With: eyes, MS

Three Alcohol Drinks Per Day May Significantly Increase Breast Cancer Risk

October 13, 2007 By MedNews Leave a Comment

It isn’t the type of alcohol but the quantity which increases a woman’s risk of contracting breast cancer.

In fact, the increased breast cancer risk from drinking three or more alcoholic drinks a day is similar to the increased breast cancer risk from smoking a pack of cigarettes or more a day, according to Kaiser Permanente researchers Yan Li, MD, PhD and Arthur Klatsky, MD.

"Population studies have consistently linked drinking alcohol to an increased risk of female breast cancer, but until now there has been little data, most of it conflicting, about an independent role played by the choice of beverage type," said Klatsky, who is presentied these findings on Sept. 27 at the European Cancer Conference (ECCO 14) in Barcelona, Spain.

The study found there was no difference between wine, beer or spirits in the risk of developing breast cancer. Even when wine was divided into red and white, there was no difference. However, when researchers looked at the relationship between breast cancer risk and total alcohol intake, they found that women who drank between one and two alcoholic drinks per day increased their risk of breast cancer by 10 percent compared with light drinkers who drank less than one drink a day. The risk of breast cancer increased by 30 percent in women who drank more than three drinks a day.

"A 30 percent increased risk is not trivial. To put it into context, it is not much different from the increased risk associated with women taking estrogenic hormones. Incidentally, in previous research completed at Kaiser Permanente, we have found that smoking a pack of cigarettes or more per day is related to a similar (30 percent) increased risk of breast cancer," Klatsky said.

Although breast cancer incidence varies between populations and only a small proportion of women are heavy drinkers, Dr Klatsky said that a 30 percent increase in the relative risk of breast cancer from heavy drinking might translate into approximately an extra 5 percent of all women developing breast cancer as a result of their habit.

"Klatsky said that all medical advice needed to be personalized to the individual. "Our findings provide more evidence for why heavy drinkers should quit or cut down."

Source: Kaiser

Filed Under: Alcohol, Cancer Tagged With: alcohol, breast cancer, cancer

List of Withdrawn Pediatric Cold Medicines

October 13, 2007 By MedNews Leave a Comment

The following medicines are among those that have been withdrawn from the market by their manufacturers for treatment of coughs and colds in infants. If you have any of these medicines at home, it would be wise to discard them to avoid accidental administration.

If you wish to use any of these medications for children between the ages of 2 -6, please contact your pediatrician for additional information. Be advised that their use in the 2-6 age group, while not covered by the current voluntary withdrawal, remains controversial.

Manufactured by Johnson & Johnson:

  • Concentrated Infants’ Tylenol Drops Plus Cold
  • Concentrated Infants’ Tylenol Drops Plus Cold & Cough
  • Pediacare Infant Drops Decongestant (PSE)
  • Pediacare Infant Drops Decongestant & Cough (PSE)
  • Pediacare Infant Dropper Decongestant (PE)
  • Pediacare Infant Dropper Long-Acting Cough
  • Pediacare Infant Dropper Decongestant & Cough (PE)

Manufactured by Novartis:

  • Triaminic Infant & Toddler Thin Strips Decongestant
  • Triaminic Infant & Toddler Thin Strips Decongestant Plus Cough

Manufactured by Prestige Brands Holding

  • Little Colds Decongestant Plus Cough
  • Little Colds Multi-Symptom Cold Formula

Manufactured by Wyeth Labs

  • Dimetapp Decongestant Infant Drops
  • Dimetapp Decongestant Plus Cough Infant Drops
  • Robitussin Infant Cough DM Drops

Source: FDA

Filed Under: Common Cold, FDA News & Alerts, Pediatrics & Parenting Tagged With: common cold, pediatrics

Baby Cold Medicines Withdrawn

October 13, 2007 By MedNews Leave a Comment

In a voluntary drug withdrawal initiated by the FDA, major manufacturers of over-the-counter cold and cough medicine targeted to infants have withdrawn their products.

The stated reason was to avoid misuse by misinformed parents. The withdrawal only affects products for infants, leaving products for use in children 2 and older on the market.

Further research, and further negotiations between pharmaceutical companies and the FDA will decide the fate of cold medicines marketed to the 2 – 6 year old population.

In the New York Times, Dr. Daniel Fratarelli, a pediatrician on the American Academy of Pediatric’s committee on drugs stated in regard to pediatric cough and cold medicines, "I don’t recommend their use in any child… These medicines don’t help, they may hurt, so don’t use them."

Filed Under: Common Cold, FDA News & Alerts, Pediatrics & Parenting Tagged With: common cold, pediatrics

Obesity linked to increased risk of esophageal cancer

October 12, 2007 By MedNews Leave a Comment

Writing in the aptly named online journal Gut, Australian researchers have discovered a disproportionate incidence of increased esophageal cancers in overweight individuals.

According to the researchers, those with a "body mass index (BMI) of 40 or more, were six times as likely than those with a BMI of between 18.25 and 25."

Gastric reflux increased the incidence of this cancer 5X, and combined with obesity, the risk increased 15X.

Men 50 years old and younger were particularly vulnerable.

Filed Under: Cancer, Diet & Weight Tagged With: cancer, esophageal cancer, obesity

« Previous Page
Next Page »

Search



Tag Cloud

alcohol allergies alzheimers antibiotics breast cancer cancer Centers for Disease Control (CDC) children cholesterol dementia depression Diabetes diet drug abuse exercise fda flu food genetics geriatrics h1n1 heart heart attack heart disease high blood pressure HIV/AIDS hormone therapy hypertension lungs menopause NIH obesity pain pediatrics pregnancy prostate cancer seniors sleep smoking statistics stroke sun teens USA women's health

Recent Comments

  • Mia Fritz on Health Benefits of Dark Chocolate
  • Shilpa on Why Too Much Iron Can Be Dangerous
  • Racheal on Teen Pregnancy May Be Reduced by Sex Education in Schools, Says Study
  • Don on Prilosec, Nexium and Prevacid Tied to Higher Risk of Pneumonia
  • Meso on Brain Changes in Elderly Can Affect Mobility and Balance
  • About Us
  • Contact

Copyright © 2025 Mednews · Log in